334993-82-7

Upstream product

• 96-32-2 bromoacetic acid methyl ester 
• 105-36-2 ethyl bromoacetate 
• 74277-17-1 N-carbamimidoyl-3,5,5-trimethyl-4,5-dihydro-pyrazole-1-carboximidic acid amide 

Downstream Products

• 871332-29-5 dimethyl {4-[{[2-amino-4-(3,5,5-trimethylpyrazolin-2-yl)-1,3,5-triazin-6-yl]methyl}methylamino]benzoyl}-L-glutamate 
• 871332-30-8 dimethyl {4-[{[2-amino-4-(3,5,5-trimethylpyrazolin-2-yl)-1,3,5-triazin-6-yl]methyl}methylamino]benzoyl}-L-aspartate 
• 871332-22-8 4-({[2-amino-4-(3,5,5-trimethylpyrazolin-2-yl)-1,3,5-triazin-6-yl]methyl}methylamino)benzoic acid 

Relevant academic research and scientific papers

Synthesis of 2,4-diamino-1,3,5-triazine analogues of methotrexate with potential antitumor activity

A series of analogues of methotrexate 23-31 in which aminopteridine ring was replaced by 2,4-diamino-1,3,5-triazine moiety were obtained. The syntheses of the analogues were accomplished by alkylation of p-aminobenzoic acids with appropriate 6-bromomethyl

Synthesis, structural characterization and antitumor activity of novel 2,4-diamino-1,3,5-triazine derivatives

The syntheses, structural elucidation based on NMR spectroscopy and X-ray analysis of 8 as well as antitumor activities of novel 2,4-diamino-1,3,5-triazine derivatives 5 and 7-22 are described. Screenings performed at NCI showed that most derivatives possessed a moderate to strong growth inhibition activity on various tumor panel cell lines between 0.148 and 56.2 μM concentrations. 2-Amino-6-bromomethyl-4-(3,5,5-trimethyl-2-pyrazoline)-l,3,5-triazine 11 showed the most potent antitumor activity with the mean midpoint values of log10 GI50, log10 TGI50 and log10 LC50 of all tests equal to -5.26, -4.81 and -4.37, respectively and therefore, it can be considered as a lead structure for further development of anticancer agents.